"Background In the TRIBE2 study, molecularly unselected and untreated mCRC patients were randomized to receive FOLFOXIRI/bevacizumab (bev) followed by the same agents after disease progression (PD) or FOLFOX/bev followed by FOLFIRI/bev after PD...Legal entity responsible for the study The author. Funding GONO Foundation."

over 4 years ago

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon) • PALB2 (Partner and localizer of BRCA2) • MSH6 (MutS homolog 6) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • ATR (Ataxia telangiectasia and Rad3-related protein) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD50 (RAD50 Double Strand Break Repair Protein) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • MRE11A (MRE11 homolog, double strand break repair nuclease) • NTRK (Neurotrophic receptor tyrosine kinase) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting)

BRAF V600E • KRAS mutation • MSI-H/dMMR • KRAS G12C • HER-2 amplification • BRAF V600 • HER-2 mutation • MET amplification • POLE mutation • KRAS G12 • MSH6 mutation • RAD50 mutation • BRAF mutation + MET amplification • POLE P286R • MSH6 F1040fs • MSH6 expression • POLE S459F

Avastin (bevacizumab)

over4years

[VIRTUAL] Tumor mutational load, microsatellite instability and actionable mutations in metastatic colorectal cancer: Results from the TRIBE2 study. (ASCO 2020)

"Background: In the TRIBE2 study molecularly unselected and untreated mCRC patients were randomized to receive FOLFOXIRI/bevacizumab (bev) followed by the same agents after disease progression (PD) or FOLFOX/bev followed by FOLFIRI/bev after PD... TML high tumors are not limited to MSI-high ones but showed POLE or MSH6 somatic mutation and shower longer PFS and OS. No differences are reported between TML low and intermediate tumors. Molecular alterations predictive of benefit from targeted strategies currently available are detectable only in a small percentage of mCRCs."

over 4 years ago

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • POLE (DNA Polymerase Epsilon) • MSH6 (MutS homolog 6) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • KRAS mutation • KRAS G12C • HER-2 amplification • BRAF V600 • HER-2 mutation • MET amplification • POLE mutation • KRAS G12 • MSH6 mutation • KRAS amplification • BRAF mutation + MET amplification • POLE P286R • BRAF amplification • MSH6 F1040fs • MSH6 expression • POLE S459F

MI Tumor Seek™

Avastin (bevacizumab)